Feasibility study of californium‐252 for the therapy of stage IV cervical cancer

Y. Maruyama; J. R. van Nagell; J. Yoneda; E. Donaldson; H. Gallion; P. Patel; R. J. Kryscio

doi:10.1002/1097-0142(19880615)61:12<2448::AID-CNCR2820611210>3.0.CO;2-E

Feasibility study of californium‐252 for the therapy of stage IV cervical cancer

Y. Maruyama, J. R. van Nagell, J. Yoneda, E. Donaldson, H. Gallion, P. Patel, R. J. Kryscio

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Twenty patients with Stage IVA and IVB cervic cancers were treated with Californium‐252 (Cf) neutron brachytherapy (NT) in a feasibility trial between 1976 and 1986. Eleven patients had Stage IVA disease; nine patients had Stage IVB disease. Patient compliance with therapy was poor in four of nine patients with Stage IVB disease, and the 50% survival time was 6 months. In Stage IVA disease there were 18% 3‐year survivals. For those that failed, the 50% survival time was 7.5 months. Because of the frequency of disseminated metastases, effective adjuvant therapy needs to be developed to use after the tumor debulking therapy, especially for Stage IVB disease. A single early Cf‐NT implant followed by 6000 cGy of whole‐pelvis fractionated radiation would accomplish this adequately for local tumor control and palliation.

Original language	English
Pages (from-to)	2448-2452
Number of pages	5
Journal	Cancer
Volume	61
Issue number	12
DOIs	https://doi.org/10.1002/1097-0142(19880615)61:12<2448::AID-CNCR2820611210>3.0.CO;2-E
State	Published - Jun 15 1988

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1097-0142(19880615)61:12<2448::AID-CNCR2820611210>3.0.CO;2-E

Cite this

@article{30fd0616958f47f7a376602cb11038bd,

title = "Feasibility study of californium‐252 for the therapy of stage IV cervical cancer",

abstract = "Twenty patients with Stage IVA and IVB cervic cancers were treated with Californium‐252 (Cf) neutron brachytherapy (NT) in a feasibility trial between 1976 and 1986. Eleven patients had Stage IVA disease; nine patients had Stage IVB disease. Patient compliance with therapy was poor in four of nine patients with Stage IVB disease, and the 50% survival time was 6 months. In Stage IVA disease there were 18% 3‐year survivals. For those that failed, the 50% survival time was 7.5 months. Because of the frequency of disseminated metastases, effective adjuvant therapy needs to be developed to use after the tumor debulking therapy, especially for Stage IVB disease. A single early Cf‐NT implant followed by 6000 cGy of whole‐pelvis fractionated radiation would accomplish this adequately for local tumor control and palliation.",

author = "Y. Maruyama and {van Nagell}, {J. R.} and J. Yoneda and E. Donaldson and H. Gallion and P. Patel and Kryscio, {R. J.}",

year = "1988",

month = jun,

day = "15",

doi = "10.1002/1097-0142(19880615)61:12<2448::AID-CNCR2820611210>3.0.CO;2-E",

language = "English",

volume = "61",

pages = "2448--2452",

number = "12",

}

TY - JOUR

T1 - Feasibility study of californium‐252 for the therapy of stage IV cervical cancer

AU - Maruyama, Y.

AU - van Nagell, J. R.

AU - Yoneda, J.

AU - Donaldson, E.

AU - Gallion, H.

AU - Patel, P.

AU - Kryscio, R. J.

PY - 1988/6/15

Y1 - 1988/6/15

N2 - Twenty patients with Stage IVA and IVB cervic cancers were treated with Californium‐252 (Cf) neutron brachytherapy (NT) in a feasibility trial between 1976 and 1986. Eleven patients had Stage IVA disease; nine patients had Stage IVB disease. Patient compliance with therapy was poor in four of nine patients with Stage IVB disease, and the 50% survival time was 6 months. In Stage IVA disease there were 18% 3‐year survivals. For those that failed, the 50% survival time was 7.5 months. Because of the frequency of disseminated metastases, effective adjuvant therapy needs to be developed to use after the tumor debulking therapy, especially for Stage IVB disease. A single early Cf‐NT implant followed by 6000 cGy of whole‐pelvis fractionated radiation would accomplish this adequately for local tumor control and palliation.

AB - Twenty patients with Stage IVA and IVB cervic cancers were treated with Californium‐252 (Cf) neutron brachytherapy (NT) in a feasibility trial between 1976 and 1986. Eleven patients had Stage IVA disease; nine patients had Stage IVB disease. Patient compliance with therapy was poor in four of nine patients with Stage IVB disease, and the 50% survival time was 6 months. In Stage IVA disease there were 18% 3‐year survivals. For those that failed, the 50% survival time was 7.5 months. Because of the frequency of disseminated metastases, effective adjuvant therapy needs to be developed to use after the tumor debulking therapy, especially for Stage IVB disease. A single early Cf‐NT implant followed by 6000 cGy of whole‐pelvis fractionated radiation would accomplish this adequately for local tumor control and palliation.

UR - http://www.scopus.com/inward/record.url?scp=0023918286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023918286&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19880615)61:12<2448::AID-CNCR2820611210>3.0.CO;2-E

DO - 10.1002/1097-0142(19880615)61:12<2448::AID-CNCR2820611210>3.0.CO;2-E

M3 - Article

C2 - 3130179

AN - SCOPUS:0023918286

SN - 0008-543X

VL - 61

SP - 2448

EP - 2452

JO - Cancer

JF - Cancer

IS - 12

ER -

Feasibility study of californium‐252 for the therapy of stage IV cervical cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this